Byongen Therapeutics Designated as a "Zhongguancun High-Tech Enterprise", Validating its Leadership in Gene Therapy R&D

BEIJING, December 16, 2024 — Beijing Byongen Therapeutics Co., Ltd. (Byongen Therapeutics) has been officially designated as a "Zhongguancun High-Tech Enterprise" by the Management Committee of Zhongguancun Science Park. This prestigious certification recognizes Byongen’s sustained investment in research and development and its innovative breakthroughs in the field of gene therapy.

Zhongguancun, often referred to as "China’s Silicon Valley," grants this status only to enterprises that demonstrate significant technological prowess, high-growth potential, and a strong portfolio of proprietary intellectual property. Receiving this designation highlights Byongen’s commitment to advancing its DynEvoLib^® platform and its success in optimizing AAV-mediated gene delivery systems.

"Being recognized as a Zhongguancun High-Tech Enterprise is a significant milestone for Byongen," said Gang Wang, Ph.D., Founder and CEO of Byongen Therapeutics. "This distinction not only validates our technical achievements in viral vector engineering but also strengthens our position within one of the world's most dynamic innovation hubs. We remain focused on leveraging our high-throughput discovery capabilities to drive high-quality development and clinical excellence."

As a newly certified high-tech enterprise, Byongen Therapeutics will continue to benefit from the region's robust innovation ecosystem, further accelerating its mission to provide precise and safe gene therapy vectors for patients worldwide.

About Byongen Therapeutics

Byongen Therapeutics is a biotechnology company focused on original innovation in AAV delivery technologies. The company aims to address core clinical delivery bottlenecks through capsid engineering. By leveraging its proprietary DynEvoLib^® platform, Byongen integrates AI, rational design, and high-throughput directed evolution to develop next-generation AAV capsids. Byongen’s R&D focus targets the development of specialized capsids for neuromuscular and central nervous system (CNS) diseases.